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Case Presentation
A 15-year-old girl was admitted to the New England Medical
Center Hospital (NEMCH) for investigation of the hypothalam-
ic-pituitary axis. Four years earlier, an eosinophilic granuloma
was discovered in the left mandible and was treated with ex-
cision and irradiation (1,000 rads). Two years earlier she devel-
oped polyuria, and a diagnosis of diabetes insipidus was made at
another hospital. She was treated with synthetic lysine vasopres-
sin nasal spray (Diapid) several times a day and noted some
symptomatic improvement. Eighteen months before admission,
her menstrual periods, which had been normal for the previous
14 months, ceased and she complained of cold intolerance, con-
stipation, and weight gain. She claimed to have grown '/2 inch
over the year prior to admission. She had occasional mild head-
aches when she did not take her medication but noted no visual
disturbances. Family history was unrevealing. Her mother was 5
ft 1 inch tall.
Physical examination revealed the following findings: blood
pressure, 110/70; heart rate, 60/mm; weight, 51.5 kg; height, 5 ft 2
inch; skin was pale and dry; optic fundi were normal; formal test-
ing for visual fields revealed no defects; there was a pale, white
lesion on the inner aspect of the right-lower jaw; the thyroid
gland was not palpable; breast development was stage III to IV;
rectal examination was normal; neurological examination was
normal.
Laboratory findings revealed the following data: hematocrit,
39%; white blood cell count, 6,700 with a normal differential;
erythrocyte sedimentation rate, 10 mm/br; urine sediment, unre-
markable; blood urea nitrogen (BUN), 12 mg; serum creatinine,
1 mg; serum calcium, 10.8 mg; serum phosphorus, 3.6 mg/l00 ml;
serum electrolytes were normal; the chest radiogram was nor-
mal; both bone scan and gallium scan revealed an area of in-
creased uptake over the right mandible.
Various tests of hypothalamic-pituitary function revealed the
following: an elevated resting prolactin level; a low T3 and T41
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with an inappropriately low level of thyroid-stimulating hormone
(TSH); an inappropriately low level of lute inizing hormone (LH)
for a patient with amenorrhea; a decreased growth hormone re-
sponse to insulin infusion; and a normal cortrosyn stimulation
test. Both TSH and LH responded normally to infusion of the
appropriate releasing hormones. Data from a water deprivation
test are shown in Table I.
The lesion in the right mandible was biopsied and again re-
vealed an eosinophilic granuloma. A second course of radiation
(800 rads) was delivered to the right mandible on an outpatient
basis. She was treated with L-thyroxin (150 pg/day), estrogen,
and lysine vasopressin nasal spray.
One year later, lysine vasopressin was discontinued in prepa-
ration for the institution of dDAVP (l-desamino-8-D arginine
vasopressin) therapy. Urine volume rose promptly to over 10 lit-
ers/day, but fell dramatically to less than 1 liter/day in response
to dDAVP (15 pg. twice daily, intranasally). A repeat biopsy of
the right mandible revealed recurrent eosinophilic granuloma.
Cerebral computerized tomographic (CT) scan showed a ques-
tionable shift of the third ventricle and deformity of the basal
cisterns. Pneumoencephlogram revealed a slight flattening of the
infundibular recess of the third ventricle and asymmetry of the
optic chiasm, but these findings were judged to be probably nor-
mal. Visual field examination was again normal. Repeat insulin
tolerance test and an arginine infusion test revealed normal
growth hormone responses. The right mandibular lesion was sur-
gically excised; no further radiation was given. The patient has
been evaluated biannually and continues to do well 2 years later.
The dose of dDAVP has been reduced to 15 pg in the morning
and 10 pg in the evening. She is asymptomatic and plans to pur-
sue a career in nursing.
Discussion
DR. ALEXANDER LEAF (Jackson Professor of
Clinical Medicine, Harvard Medical School, Chief;
Medical Services, Massachusetts General Hospi-
tal): Neurogenic diabetes insipidus is a clinically
rare but physiologically important disturbance of
water balance. Its pathophysiology is as clearly un-
derstood as is any aspect of renal physiology and
endocrine homeostasis. It results from a failure of
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Table 1. Water deprivation test.
Weight Urin
(kg) Posma Uosm5
e Volume
(ml)
Day 1 Vasopressin discontinued
10:00p.m. 51.5 283 200 —
Day 2
8:00a.m.
9:00a.m.
10:00a.m.
11:00a.m.
12:00 noon
50.9 291 154
— —
—
50.1 — 53
—
— 57
49.3 309 67
530
420
280
280
500
—Pitressin tannate in oil, 5U—
at 12:00 noon
1:30p.m.
2:00p.m.
4:00p.m.
5:00p.m.
6:00p.m.
Day 3
8:00a.m.
—
—
747
802
823
51.5 — 1169
400
38
30
17
10
—
a Posm = plasma osmolality
Uosm = urine osmolality
NPO = nothing by mouth (after 10:00 p.m.)
antidiuretic hormone (ADH) secretion in response
to the physiologic stimulus of water deficiency. This
is the condition that our patient has and for which
she exhibits all the classical and essential diagnostic
criteria.
Since the classic studies of Verney [1] in the mid-
1940s, it has been evident that the neurohypophysis
plays a fundamental role in the economy of body
fluids and in the regulation of the tonicity of the
body fluids. This it does in combination with the
thirst mechanism as established a decade later by
Andersson [2]. The resulting "double negative"
feedback system which sustains our serum sodium
concentrations constant between some 136 and 143
mEq/liter and the corresponding serum osmolality
between 275 and 290 mosm/kg of water is shown in
Figure 1. Cell membranes are generally so per-
meable to water that a single tonicity—chemical po-
tential of water—exists throughout all body fluid
compartments. Thus this neurohypophysis-thirst-
renal axis accounts for the constancy of serum so-
dium concentration and of osmolality of intra-
cellular as well as extracellular fluids. It is so ef-
fective that the range of values that we accept as
normal probably represents largely analytical rather
than biologic variation.
With loss of neurohypophyseal function the situa-
tion changes as shown in Figure 2. Thus, even when
the ADH limb of the "double negative" regulatory
feedback is lost, the thirst mechanism still pre-
serves a serum sodium and osmolality within the
normal range but at the expense of pronounced
polydipsia and polyuria. It is true that statistically
the serum sodium concentration or osmolality of an
untreated patient with diabetes insipidus may be
slightly higher than the mean normal value, but the
range of the latter prevents such small increases
from having any diagnostic significance. Thus Bar-
low and de Wardner [3] found the plasma osmolality
of patients suffering from diabetes insipidus to aver-
age 295 15 mOsm!kg of water (SD), whereas that
for normal subjects averaged 280 6 mOsmlkg of
water (SD). Since this statistically significant dif-
ference is associated with considerable overlap this
determination is of little help diagnostically in the
individual patient.
When unconsciousness or lack of water occurs,
however, the patient with diabetes insipidus will
continue to lose water with resulting weight loss
and increase in serum osmolality. Dehydration of a
serious degree can occur rapidly in such circum-
stances. This sequence is depicted nicely in the pro-
vocative diagnostic tests shown for our patient in
Table I. When fluids were withheld after 10 p.m.,
the bladder contained a large volume of urine the
following morning. The hourly urine flow remained
high, its concentration fell to minimal levels, the pa-
tient lost weight, and her serum osmolality in-
creased from a normal level of 283 to 309 mOsm/kg
of water. The values show good internal con-
sistency since the patient lost 2.2 kg during the 14
hours of water restriction and had a negative fluid
balance by urine losses alone of 2.01 kg; her serum
osmolality increased thereby to 309 mOsm/kg
whereas the theoretical expected final osmolality
would be some 305 mOsm/kg, assuming an initial
Water loss
Serum tonicity/
ADH release
Tubular reabsorption
of water
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Water lost
Fig. 1. The thirst-ADH-renal axis that functions to preserve the
normal osmolality of body fluids—a double negative feedback
control system.
574 Nephrology Forum
total body water content of 60% of body weight.
Her urine concentration fell to values close to maxi-
mal dilution capacity despite the increasing dehy-
dration. Thus, her kidneys failed to show any ability
to conserve body water in the face of increasing de-
hydration. It remained only to demonstrate that her
renal tubules could conserve water when exposed
to ADH: in fact, when pitressin tannate in oil was
administered, her urine volume fell rapidly and
urine osmolality rose to high levels. Her tubules
could respond to ADH and her diabetes insipidus,
therefore, was neurogenic due to insufficiency of
ADH secretion.
In summary, the patient demonstrated the two
physiologic features which are the sine qua non for
the diagnosis of neurogenic diabetes insipidus: (1)
she failed to concentrate her urine despite serum Os-
molality rising to abnormally high levels; (2) her
kidneys responded to exogenous vasopressin by
elaborating a concentrated urine. Without both fea-
tures, one cannot make a diagnosis of neurogenic
diabetes insipidus since polyuria with a dilute urine,
which is unresponsive to vasopressin, occurs in a
variety of disorders including: nephrogenic diabetes
insipidus, chronic renal disease, kaliopenic ne-
phropathy, and hypercalcemia.
Nephrogenic diabetes insipidus is congenital,
makes its appearance shortly after birth, occurs pre-
dominantly in males, and appears to result from ge-
netic deficiency of adenylate cyclase responsive to
ADH in the renal tubules. The other three condi-
tions usually show stigmata of the disease or distur-
bance causing them and should not be difficult to
diagnose.
Other provocative tests have been utilized in the
diagnosis of diabetes insipidus. Infusion of hyper-
tonic saline to elevate serum osmolality and thus to
provide the stimulus for ADH release has been
Water loss
Serum tonicity
Thirst
Water intake/
Dilution of body
fluids
Water loss ft
Fig. 2. Schemata a neurogenic diabetes insipidus. In neurogenic
diabetes insipidus, the control of the osmolality of body fluids
depends solely upon the operation of the thirst mechanism be-
cause the ADH-renal feedback control is lost. Serum tonicity can
be maintained within normal limits but only at the expense of
polyuria and polydipsia.
used, as has pharmacologic stimulation of ADH re-
lease with nicotine. The simple overnight dehy-
dration test, however, as applied to this patient is
by far the most satisfactory diagnostic test. None-
theless, one must be aware that in the youngster
with presumptive diabetes insipidus dangerous lev-
els of negative water balance may develop rapidly;
thus, urine volumes and weight must be followed
carefully to avoid serious consequences of dehy-
dration. Similar precaution must be exercised in
testing the obtunded or mentally confused adult.
A more troublesome differential diagnosis occa-
sionally exists in relation to primary polydipsia.
This disorder is generally a manifestation of a func-
tional mental illness, usually called compulsive wa-
ter drinking or psychogenic polydipsia. The diag-
nostic difficulty arises from the fact that prolonged
very high fluid intake itself impairs renal con-
centrating ability. Figure 3 shows the serum and
urine osmolalities of normal subjects, patients with
diabetes insipidus, and of two patients with psy-
chogenic polydipsia [4]. After 8 hours of fluid re-
striction, the normal subjects had serum os-
molalities within the usual range and were excreting
a concentrated urine. The patients with diabetes in-
sipidus, both neurogenic and nephrogenic, devel-
oped high serum osmolalities while their urine ton-
icity persisted very dilute. The patients with psy-
chogenic polydipsia had serum osmolalities that
were normal and urine concentrations that were
low, but overlapped the lower limits of the normals.
When neurohypophyseal insufficiency is not com-
plete, overlap may occur between psychogenic
polydipsia and incomplete diabetes insipidus. It is
useful, however, to remember a point made by Bar-
low and de Wardener, namely, that patients with
neurogenic diabetes insipidus concentrate their
urine better with exogenous ADH than following
dehydration; whereas normal subjects or those with
psychogenic polydipsia elaborate a more concen-
trated urine following water restriction than in re-
sponse to exogenous ADH, irrespective of the ab-
solute levels of the urine concentration attained [3].
At the level of the kidney, the major action of the
neurohypophyseal hormone has been character-
ized. Specifically, ADH increases the permeability
of the luminal plasma membranes of the cortical
collecting ducts to water and of the medullary col-
lecting ducts to water and urea. It may also enhance
salt reabsorption in the thick ascending limb of
Henle's loop, which generates the hypertonic med-
ullary interstitium and makes possible the elabora-
tion of a concentrated urine.
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Nephrogenic
Diabetes diabetes Psychogenic
Normals insi pidu s I nsip idus polyd psia
(29) (7) (3) (2)
Diabetes insipidus is itself a benign condition so
long as adequate water, or replacement therapy, or
both is available. Because loss of neurohypophy-
seal function however may have different etiolo-
gies, not all of which are benign, it is important to
learn if possible the cause in each case. Randall has
suggested an etiologic classification of diabetes in-
sipidus with two major categories, primary and sec-
ondary [5]. Primary diabetes insipidus includes fa-
milial and idiopathic cases. Idiopathic cases consti-
tute the major group in any such classification,
comprising 45% of Blotner's series [6] but perhaps
exceeded today by head injuries, iatrogenic or acci-
dental. Idiopathic diabetes insipidus may become
manifest at any age and may affect either sex. It is
unusual for the idiopathic type to appear early in
infancy, as does nephrogenic diabetes insipidus, al-
though it may develop in childhood. Familial diabe-
tes insipidus, on the other hand, is very uncommon
and constitutes less than 1% of cases. It may be-
come manifest in infancy and may affect either sex.
The condition has been described in seven genera-
tions of one family [7].
In the group with secondary diabetes insipidus,
head trauma—accidental or neurosurgical—and
neoplasms—primary or metastatic—constitute the
major causes. In older series, primary intracranial
tumors constituted nearly one-third of all cases.
The currently increasing incidence of automobile
injuries, surgical pituitary stalk sections, and other
neurosurgical procedures in the neighborhood of
the neurohypophyseal system has affected the fre-
quency of secondary diabetes insipidus. Of the met-
astatic tumors, breast cancer and lung cancer seem
to have special predilection for the hypothalamus.
Other etiologic factors contribute only small num-
bers to any series. However, sarcoidosis, birth in-
juries, eosinophilic granuloma—as our patient
has—and a variety of local infections appear on any
listing of extensive causes of diabetes insipidus.
Even with disease or tumor within the hypothala-
mus, diabetes insipidus is unusual. With loss or de-
struction of the posterior pituitary gland, diabetes
insipidus may be short lived or nonexistent because
the active hormone, which is synthesized in the su-
praoptic nuclei and to a lesser degree in the para-
ventricular nuclei, is transmitted down the supra-
opticohypophyseal tract and stored for release in the
posterior pituitary. The hormone can be released
from the higher levels of the tract when lower por-
tions are damaged or destroyed, thus preventing
manifest diabetes insipidus.
This capability of higher levels within the hypo-
thalamus to subsume the secretion of ADH when
lower portions of the supraopticohypophyseal tract
have been damaged was described by Fischer, In-
gram, and Ranson [8] in experimental diabetes in-
sipidus and probably accounts for the variable clini-
cal course. I have seen complete diabetes insipidus
following head trauma, which after maintaining a
flagrant course for 3 years subsided, with replace-
ment therapy no longer needed and with return of
concentrating ability. On the other hand, I have
seen diabetes insipidus start at 1 p.m. on a Saturday
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Fig. 3. Mean and range of serum and urine osmolalities after 8-
hour dehydration. (Data taken front reference 4 by permission
of Journal of Clinical Endocrinology and Metabolism).
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afternoon, cease abruptly 2 weeks later, and never
return!
Given the evidence from biopsies of the man-
dible, we can presume that eosinophilic granuloma
is the cause of diabetes insipidus in the patient un-
der discussion today. Eosinophilic granuloma is fre-
quently multifocal, often involves the mandible,
and may affect both the bones and viscera. In the
brain, the hypothalamus is most commonly affected
but sometimes the cerebellum and cortex are in-
volved. A lesion in the hypothalamus in our patient
would account not only for the diabetes insipidus
but also for the other endocrine changes elicited by
the provocative tests of hypothalamic-pituitary
function.
Thus, the elevated resting prolactin level is con-
sistent with loss of the hypothalamic prolactin in-
hibitory factor (PIF). The low peripheral thyroid
hormone levels and low level of the pituitary thy-
roid-stimulating hormone (TSH) is consistent with
decreased or absent hypothalamic thyrotropin re-
leasing hormone (TRH). The normal response of
TSH to infusion of TRH confirms the hypothalamus
as the site of the primary deficiency. The low level
of LH and its normal response to infusion of lutein-
otrophin releasing hormone (LRH) has the same in-
terpretation as does the diminished growth hor-
mone response to hypoglycemic stress, which
points to a deficiency of hypothalamic growth hor-
mone releasing factor (GHR). All of these tests in-
dicate a lesion of the hypothalamus. The normal
cortrosyn stimulation test of the adrenal cortex is
reassuring evidence that glucocorticoid function is
adequate. Although adrenal insufficiency may result
from eosinophilic granuloma, we had strong evi-
dence of normal adrenal cortical function in this pa-
tient from the observation that she could elaborate
large volumes of very dilute urine. This capability is
lost with adrenal or anterior pituitary failure even in
the presence of neurogenic diabetes insipidus,
though the mechanism of the lost ability to excrete a
copious dilute urine with loss of both ADH and ad-
renal cortical secretions is still not well understood.
Although the function of this exercise is to dis-
cuss the disturbance in water metabolism, a word
should be said regarding the patient's underlying
problem, multifocal eosinophilic granuloma—a
very confusing clinical entity or entities! Multifocal
eosinophilic granuloma often makes its first appear-
ance as a bony lesion of the mandible, mastoid, or
skull. But when diabetes insipidus is the first mani-
festation, it is caused by granulomas within the hy-
pothalamus, as in our patient, and not by pressure
from adjacent bony tumors. Other soft tissue or-
gans, such as the liver, spleen, lymph nodes, and
skin, may also be involved. Evidence for cerebral
and cerebellar dysfunction may also be present. An-
terior pituitary failure rarely develops in the course
of this enigmatic disease, but whether this compli-
cation is the result of loss of hypothalamic trophic
factors or direct destruction of the anterior pituitary
by granuloma has not been settled by either hor-
mone assays or postmortem studies to my knowl-
edge.
Treatment of eosinophilic granuloma by surgical
excision or radiation of local solitary bone lesions is
usually successful. In multifocal eosinophilic gran-
uloma beneficial results have been reported with
chemotherapy including vinbiastine, prednisone,
mercaptopurine, or methotrexate singly or in vari-
ous combinations. Once the diabetes insipidus is es-
tablished, however, it does not respond to treat-
ment of the underlying eosinophilic granuloma.
Finally, a word should be said regarding the ther-
apy of diabetes insipidus. The condition has no
known deleterious effect on health so long as its
cause is benign and so long as water is available, the
subject is conscious, and the thirst center is func-
tioning. Thus, the indications for replacement ther-
apy may not be pressing. The marked polyuria and
polydipsia with complete lack of ADH activity usu-
ally is disturbing and socially distressing during the
day and may interfere with sleep at night. For rea-
sons of convenience and comfort replacement ther-
apy is usually justified.
Fortunately, several modes of therapy are avail-
able. A variety of ADH sprays and powders for in-
tranasal insuffiation, as well as ADH for injection,
have been the standard replacement therapy. Ly-
sine vasopressin spray provides control of polyuria
for relatively short periods of 2 to 6 hours, in-
sufficient for an undisturbed night's sleep. Moisten-
ing a pledget of cotton, however, with the solution
of hormone and inserting it into a nostril at bed time
is used by some to obtain an undisturbed night. Pi-
tressin tannate in oil (5 U/mI) is potent and effective
for 24 to 72 hours. It requires a deep subcutaneous
or intramuscular injection by a fairly large gauge
needle because of the viscosity of the oil vehicle.
This material causes sterile abscesses in some sub-
jects. Care must be taken to allow return of polyuria
and polydipsia between injections in order to avoid
cumulative water retention and severe hyponatre-
mia. The main drawbacks of pitressin tannate are,
however, the discomforts and inconvenience at-
tended upon any preparation that must be adminis-
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tered parenterally. Aqueous vasopressin (20 pres-
sor units per ml), when it is available, plays virtual-
ly no role in the management of chronic diabetes
insipidus. It does allow a readily controllable meth-
od of treating the comatose patient with head
trauma and polyuria when the pitressin is diluted
and administered intravenously. Since aqueous pi-
tressin is degraded very rapidly its action ceases
within minutes after the infusion is stopped. This
property makes it worthless in the management of
chronic diabetes insipidus. One young patient of
mine had a sister who was a nurse. The sister inject-
ed the patient subcutaneously with 1 ml of the aque-
ous hormone preparation four times daily—a total
of 80 pressor units! With each injection the patient
experienced general abdominal and uterine cramps,
perioral blanching, and 30 to 60 minutes of de-
creased urine output. Later we found that 2 units of
pitressin administered as the long-acting pitressin
tannate in oil controlled her symptoms for over 24
hours.
In the mid-1960s, structure-activity investigations
were performed in Czechoslovakia with a variety of
synthetic analogues of vasopressin [91. From these
studies emerged a substituion of D for L arginine at
position 8 which resulted in a peptide, DAVP, with
diminished vasopressor activity. Deamination of
the hemicystein at position 1 gave rise to a second
peptide, dAVP, with enhanced antidiuretic to pres-
sor activity and prolonged duration of action. Com-
bining both changes in one molecule, that is, deami-
nation at position 1 and substitution of D for L argi-
nine in position 8 results in a peptide, dDAVP, with
high antidiuretic to pressor potency (approximately
2000:1) and a prolonged duration of action (6 to 24
hours), as compared with the natural hormone AVP
(AD:P = 1) and duration of action (2 to 4 hours) [10,
11]. This compound, dDAVP, is available for ad-
ministration intranasally, and the experience to date
indicates it to be a safe and effective means of con-
trol. Generally, administration twice daily in doses
as low as 5 to 20 suffices in many patients. Local
nasal irritation and systemic reactions are rare. An
occasional patient may complain of headaches, and
that is about all the side reactions that have been
noted. The medication is readily self-administered
intranasally by a plastic catheter (Rhinyle®; A. B.
Ferring Company, Malmo, Sweden).
Though intranasal dDAVP is the treatment of
choice for diabetes insipidus, it is well to remember
that alternatives to hormone replacement may be
helpful at times. Since, with a very dilute urine of
fixed osmolality, the urine volume is determined by
the solute load requiring excretion, a reduction
chiefly of salt and protein in the diet will reduce the
major urinary solutes and thus the volume of urine
necessary to accommodate their excretion. A diu-
retic such as chlorothiazide administered chronical-
ly will maintain a state of mild sodium depletion
which impairs "free water" excretion by the kid-
neys and thus reduces urine volume from dis-
tressing levels of 6 to 10 liters daily to volumes of 2
to 4 liters. Chlorpropamide seems to potentiate the
action of even small amounts of circulating anti-
diuretic hormone and may thereby enhance anti-
diuresis when neurohypophyseal failure is not com-
plete. Severe hypoglycemia may be a complicating
aspect of this therapy and is especially harmful in
the young patient. Thus, dDAVP by intranasal ad-
ministration seems today the safest and most ef-
fective form of therapy for this distressing condi-
tion.
Questions and Answers
DR. SEYMOUR REICHLIN (Chief, Endocrinology,
NEMCH): We assessed the location of the lesion in
this patient to be precisely where you did. It is real-
ly the only site where a small lesion can destroy
antidiuretic function and some, but not all, anterior
pituitary functions without producing other gross
physiologic abnormalities [12]. A very small lesion
is responsible it seems.
DR. J. J. COHEN: Dr. Reichlin, considering the
propensity of lesions such as this to recur and to
grow, is it surprising to you that the patient has not
shown more evidence of difficulty over a rather long
period of time? Is it safe to follow a patient in this
fashion?
DR. S. REIcHLIN: it has been difficult to decide
how to manage this patient. The possibility of an
expanding granulomatous mass in the hypothala-
mus that might produce progressive damage has
concerned us because some cases have been report-
ed in which rapid expansion of an eosinophilic gran-
uloma has caused death. On the other hand, we feel
we can monitor the lesion by the use of the CT scan
and by careful clinical evaluation. We have been
concerned about exposing the hypothalamus to a
tumorcidal dose of radiation and thus endangering
the patient's residual hypothalamic function. We
have been on the horns of a dilemma, that is, to
produce further damage versus protect her from tu-
mor growth. We have elected to follow a con-
servative approach of watchful waiting. The lesion
has not progressed for 5 years, and, as Dr. Leaf
mentioned, these lesions have a rather variable
course, sometimes remitting spontaneously.
DR. A. LEAF: I certainly support your decision.
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We have seen comparable lesions appear in a bone
and disappear spontaneously. The deaths that have
been reported from this condition generally occur
when the viscera are involved, and this patient
shows no evidence of such involvement. The condi-
tion can remain stable for many years, and for this
reason I think it is wise to be conservative. Do you
wish to comment, Dr. Reichlin, on the relationship
of diabetes insipidus secondary to eosinophilic
granuloma and other hormonal disturbances?
DR. S. REICHLIN: Dr. Goodman reviewed this lit-
erature recently after we encountered a patient with
direct pituitary destruction due to the eosinophilic
granuloma. Perhaps he could comment.
DR. RICHARD H. GOODMAN (Fellow, Endocrinol-
ogy, NEMCH): We were not able to find any cases
in which there was involvement of the anterior pitu-
itary by eosinophilic granuloma, but the posterior
pituitary was sometimes involved. It is interesting
that in this patient, as in some others previously de-
scribed, growth hormone responses increased after
a period of vasopressin therapy for the diabetes in-
sipidus. Treatment with either thyroxine or estro-
gen or both may also have improved the growth
hormone response in the patient described today.
DR. S. REICHLIN: Although growth hormone is
released following vasopressin administration, in-
numerable studies show that vasopressin is not a
GHR. Normal growth hormone secretory dynamics
can be demonstrated in rats with the Brattleboro
strain of congenital diabetes insipidus. Studies have
shown that these animals have cyclical growth hor-
mone secretion. It is possible that improvement of
the general physical condition of the patient im-
proves growth hormone secretion in a fairly non-
specific way.
DR. MARK E. MOLITCH Endocrinology,
NEMCH): We have seen several instances of tran-
sient diabetes insipidus after pituitary surgery in
which the condition persisted for several months or
longer. The pathophysiology of the diabetes insip-
idus and the slow recovery of antidiuretic function
have never been clear to me. Can you clarify it?
DR. A. LEAF: I can refer you to the excellent
study by Fischer, Ingram, and Ranson [8]. They
produced stereotactic lesions in cats and found that
the animals went through several phases. Immedi-
ately after surgery there was a very intense anti-
diuresis, then a phase in which polyuria occurred
and was followed by mild antidiuresis, and finally
permanent diabetes insipidus developed if the le-
sion was produced in the right location. They attrib-
uted the initial antidiuresis to release of stored hor-
mone and the subsequent polyuria and mild anti-
diuresis to a period of decreased hormone
availability. The final permanent diabetes insipidus
resulted if a lesion had been produced that pre-
vented further hormone secretion. They found that
even if they transsected the supraopticalhypophys-
eal tract low down, the mamillary bodies in the hy-
pothalamus could actually take over the hormone
secretion; thus, the posterior pituitary could be de-
stroyed and yet permanent diabetes insipidus not
develop. I think the slow recovery that sometimes
occurs is due to the subsiding of the response to the
trauma in the higher portions of the tract. This res-
toration allows the hormone to be released at higher
levels, closer to the supraoptic nuclei where it is
formed. That is my interpretation of the physiologic
events when recovery is delayed as long as a year.
DR. J. J. COHEN: There is convincing evidence
that volume "receptors" and other nonosmolar fac-
tors also control ADH release. Do the osmolar and
nonosmolar mechanisms operate through the same
neurons or are there different pathways involved?
Also, do nonosmolar factors affect hormone syn-
thesis or just hormone release?
DR. S. REICHLIN: The supraoptic neuron is
played upon by a variety of impulses. The opiates
should be mentioned because recent evidence in-
dicates that endorphins activate the supraoptic neu-
rons directly. This mechanism apparently accounts
for morphine-induced antidiuresis. These very same
neurons are responsive to acetylcholine, which me-
diates the right auricular and volume controls. They
are also responsive to norepinephrine and to both
sodium shifts and osmotic changes. Angiotensin II
also appears to act directly on supraoptic neurons.
This provides a mechanism through which de-
creased blood volume could signal ADH release.
The osmoreceptor area contains integrating cells,
the membranes of which process a great deal of
neurotransmitter information from all parts of the
body: blood chemistry, volume receptors, and
probably psychological data as well. They are im-
pressively versatile neurons.
DR. J. J. COHEN: I was trying to determine
whether all cells in this area serve this integrating
function or whether separate cells have different
roles, which in the aggregate give rise to the ob-
served, integrated behavior.
DR. S. REICHLIN: It has not been possible to an-
swer that question with confidence because the best
data are obtained by placing an electrode into the
neuron itself. Hayward [13] found that a certain
proportion of such cells will discharge repetitively
when hypertonic saline is injected into the carotid
artery.
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DR. NIcoLAos E. MADIAS (Renal Service,
NEMCH): Could you comment on recent observa-
tions that show a linkage between ADH and prosta-
glandins; namely, that ADH stimulates the produc-
tion of prostaglandins, and that prostaglandins an-
tagonize the hydroosmotic effect of ADH [14-17]. A
study in the Brattleboro rat shows that the excre-
tion of prostaglandin E2 is very low and that it in-
creases significantly after injection of ADH [14]. Do
you envision a role for this system in the diagnosis
and treatment of diabetes insipidus?
DR. A. LEAF: I think this area needs more explo-
ration. You described the state of the art as well as I
know it in your comments: ADH seems to effect the
synthesis of prostaglandins by releasing arachia-
donic acid and evoking synthesis. There are many
potentials for interplay that must have some physio-
logic and clinical significance, but they need to be
developed.
DR. J. P. KASSIRER: We've seen in recent years
an explosion in the number of drugs that have no-
table effects on water balance. Some, in particular
chlorpropamide, appear to have some important
therapeutic properties. What are the current
thoughts on the mechanism of action of chiorpropa-
mide?
DR. A. LEAF: I haven't studied chiorpropamide
myself. Two studies have described differing physi-
ologic mechanisms at work, One study in the toad
bladder demonstrated evidence that chlorpropa-
mide potentiates the effects of small amounts of
ADH on the permeability to water [18]. Another
study argued that the drug caused the release of
ADH from the neurohypophysis [19]. The presence
of ADH seems to be necessary for chiorpropamide
to work. If there is still some residual function, that
effect may be of therapeutic value. I think today
with other modes of therapy available it is probably
advisable not to use chlorpropamide, particularly in
children because of the risk of hypoglycemia.
DR. WILLIAM E. COBB (Endocrinology,
NEMCH): Several patients have been described in
the literature with diabetes insipidus and absolute
diminished thirst. Some have had essential hyper-
natremia, high sodium levels, and no response to
osmotic stimuli. It has been suggested that chlor-
propamide is probably the drug of choice for treat-
ing this group of patients. It has also been suggested
that perhaps chiorpropamide has an effect on the
thirst center. Do you know of any data that would
support this hypothesis?
DR. A. LEAF: I don't. I think that this entity does
not result from a single etiology. I think that it is
possible to have a lesion in the hypothalamus that
destroys the neurons responsible for thirst and also
those responsible for osmoregulation. Though these
neurons are apparently separable, both centers are
located close together in the lateral preoptic and su-
praoptic areas of the anterior hypothalamus, re-
spectively. I have no experience with possible ef-
fects of chlorpropamide on thirst or its use in these
very rare cases.
DR. J. P. KASSIRER: Dr. Cobb, would you elabo-
rate a bit on your studies of therapy with a synthetic
analogue of vasopressin?
DR. W. E. COBB: As Dr. Leaf mentioned before,
dDVAP has a longer duration of action and a much
higher antidiuretic to pressor potency than the par-
ent compound, AVP. We studied intranasal dDAVP
in 29 patients with chronic and 2 patients with
acute—that is, postoperative —diabetes insipidus
[20]. Twenty-eight patients with chronic neurogenic
diabetes insipidus, who have now been followed for
up to 35 months, achieved excellent control of
symptoms at a dose of 2.5 to 15.0 g, once every 8
to 24 hours. One patient, initially well controlled on
10 tg, twice daily, developed partial resistance to
dDAVP and presently requires a dose of 15 to 20
g, four times daily. Headache occurred in the "re-
sistant" patient at high doses (over 20 tg) and in
one additional patient at a dose of 10 In each of
two patients who developed acute diabetes insip-
idus after transfrontal removal of a craniopharyngi-
oma, 5 tg intranasal dDAVP every 14 to 18 hours
was effective. We have not used dDAVP to treat
acute diabetes insipidus after transsphenoidal hy-
pophysectomy because of surgically induced con-
tusion and swelling of nasal mucus membranes.
In patients with chronic diabetes insipidus,
dDAVP resulted in a degree of control superior to
that of chlorpropamide or lysine vasopressin nasal
spray and as good as that obtained with vasopressin
tannate in oil. The frequent occurrence of side ef-
fects with chlorpropamide—hypoglycemia, reac-
tions similar to those seen with antabuse—and
vasopressin tannate in oil—sterile abscesses, ab-
dominal pain—especially in children, was in
marked contrast to the low frequency and minor na-
ture of side effects with dDAVP. We feel that intra-
nasal dDAVP is the preferred treatment of chronic
diabetes insipidus in both children and adults, and
of acute postoperative diabetes insipidus following
transfrontal surgery. Hopefully, the cost of this
drug will fall in the near future and thus make it pos-
sible to exploit its advantages more widely.
Reprint requests to Dr. Alexander Leaf, Chief, Medical Serv-
ices, Massachusetts General Hospital, Boston, Massachusetts
02114
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